{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T18:09:10Z","timestamp":1768414150723,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07154"],"award-info":[{"award-number":["20K07154"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["JPMJFS2126"],"award-info":[{"award-number":["JPMJFS2126"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons. Endoplasmic reticulum (ER) stress contributes to PD pathogenesis, with the ER-associated degradation (ERAD) system playing a protective role. HRD1, an ER-resident ubiquitin ligase, and its stabilizer SEL1L are involved in ERAD and neuronal survival. This study investigated alterations in the plasma levels of microRNA-101 (miR-101), which targets SEL1L, in patients with PD, and its potential role as a biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Plasma miR-101 levels in patients with PD significantly decreased compared with those in healthy controls. Receiver operating characteristic curve analysis demonstrated that miR-101 could moderately discriminate patients with PD from healthy individuals (area under the curve\u2009=\u20090.781, 95% confidence interval\u2009=\u20090.547\u20131.00). The optimal cutoff, as determined by the Youden index, was 0.737 (expression ratio relative to that in the healthy control group), yielding a sensitivity of 50% and specificity of 100%. These results suggested that reduced plasma miR-101 expression may reflect the pathophysiological state of PD, and miR-101 has potential as minimally invasive biomarker for PD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-025-07604-6","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:44:15Z","timestamp":1765367055000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma expression levels of microRNA-101 are downregulated in patients with Parkinson\u2019s disease"],"prefix":"10.1186","volume":"19","author":[{"given":"Tomohiro","family":"Omura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Nishiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Kaneda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Kitahiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Itohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyasu","family":"Sakane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuko","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"7604_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384\u20136.","journal-title":"Neurology"},{"key":"7604_CR2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/alz.12328","volume":"17","author":"Alzheimer's Association","year":"2021","unstructured":"Alzheimer\u2019s Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2021;17:327\u2013406.","journal-title":"Alzheimers Dement"},{"key":"7604_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/brain\/122.8.1437","volume":"122","author":"P Damier","year":"1999","unstructured":"Damier P, Hirsch EC, Agid Y, Graybiel AM. Patterns of loss of dopamine-containing neurons in parkinson\u2019s disease. Brain. 1999;122:1437\u201348.","journal-title":"Brain"},{"key":"7604_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311:1670\u201383.","journal-title":"JAMA"},{"key":"7604_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.neuron.2016.03.038","volume":"90","author":"PP Michel","year":"2016","unstructured":"Michel PP, Hirsch EC, Hunot S. Understanding dopaminergic cell death pathways in Parkinson disease. Neuron. 2016;90:675\u201391.","journal-title":"Neuron"},{"key":"7604_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.toxlet.2020.01.019","volume":"324","author":"Z Mou","year":"2020","unstructured":"Mou Z, Yuan YH, Zhang Z, Song LK, Chen NH. Endoplasmic reticulum stress, an important factor in the development of parkinson\u2019s disease. Toxicol Lett. 2020;324:20\u20139.","journal-title":"Toxicol Lett"},{"key":"7604_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev.biochem.73.011303.074134","volume":"74","author":"M Schr\u00f6der","year":"2005","unstructured":"Schr\u00f6der M, Kaufman RJ. The mammalian unfolded protein response. Annu Rev Biochem. 2005;74:739\u201389.","journal-title":"Annu Rev Biochem"},{"key":"7604_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1146\/annurev.biochem.67.1.425","volume":"67","author":"A Hershko","year":"1998","unstructured":"Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425\u201379.","journal-title":"Annu Rev Biochem"},{"key":"7604_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1742-4658.2007.05639.x","volume":"274","author":"H Yoshida","year":"2007","unstructured":"Yoshida H. ER stress and diseases. FEBS J. 2007;274:630\u201358.","journal-title":"FEBS J"},{"key":"7604_CR10","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0014-5793(02)03660-8","volume":"532","author":"M Kaneko","year":"2002","unstructured":"Kaneko M, Ishiguro M, Niinuma Y, Uesugi M, Nomura Y. Human HRD1 protects against ER stress-induced apoptosis through ER-associated degradation. FEBS Lett. 2002;532:147\u201352.","journal-title":"FEBS Lett"},{"key":"7604_CR11","doi-asserted-by":"publisher","first-page":"16929","DOI":"10.1074\/jbc.M110.215871","volume":"286","author":"Y Iida","year":"2011","unstructured":"Iida Y, Fujimori T, Okawa K, Nagata K, Wada I, Hosokawa N. SEL1L protein critically determines the stability of the HRD1-SEL1L endoplasmic reticulum-associated degradation (ERAD) complex to optimize the degradation kinetics of ERAD substrates. J Biol Chem. 2011;286:16929\u201339.","journal-title":"J Biol Chem"},{"key":"7604_CR12","doi-asserted-by":"publisher","first-page":"E582","DOI":"10.1073\/pnas.1318114111","volume":"111","author":"S Sun","year":"2014","unstructured":"Sun S, Shi G, Han X, Francisco AB, Ji Y, Mendon\u00e7a N, et al. Sel1L is indispensable for mammalian endoplasmic reticulum-associated degradation, endoplasmic reticulum homeostasis, and survival. Proc Natl Acad Sci U S A. 2014;111:E582\u201391.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7604_CR13","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/jnr.21616","volume":"86","author":"T Omura","year":"2008","unstructured":"Omura T, Kaneko M, Tabei N, Okuma Y, Nomura Y. Immunohistochemical localization of a ubiquitin ligase HRD1 in murine brain. J Neurosci Res. 2008;86:1577\u201387.","journal-title":"J Neurosci Res"},{"key":"7604_CR14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/S0092-8674(01)00407-X","volume":"105","author":"Y Imai","year":"2001","unstructured":"Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell. 2001;105:891\u2013902.","journal-title":"Cell"},{"key":"7604_CR15","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1111\/j.1471-4159.2006.04155.x","volume":"99","author":"T Omura","year":"2006","unstructured":"Omura T, Kaneko M, Okuma Y, Orba Y, Nagashima K, Takahashi R, et al. A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a substrate of Parkin. J Neurochem. 2006;99:1456\u201369.","journal-title":"J Neurochem"},{"key":"7604_CR16","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nrl.2015.06.011","volume":"32","author":"D Hernandez-Baltazar","year":"2017","unstructured":"Hernandez-Baltazar D, Zavala-Flores LM, Villanueva-Olivo A. The 6-hydroxydopamine model and parkinsonian pathophysiology: novel findings in an older model. Neurologia. 2017;32:533\u20139.","journal-title":"Neurologia"},{"key":"7604_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.33549\/physiolres.933895","volume":"68","author":"S Salari","year":"2019","unstructured":"Salari S, Bagheri M. In vivo, in vitro and pharmacologic models of parkinson\u2019s disease. Physiol Res. 2019;68:17\u201324.","journal-title":"Physiol Res"},{"key":"7604_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.bbrc.2018.10.094","volume":"506","author":"T Omura","year":"2018","unstructured":"Omura T, Matsuda H, Nomura L, Imai S, Denda M, Nakagawa S, et al. Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson\u2019s disease. Biochem Biophys Res Commun. 2018;506:516\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"7604_CR19","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1038\/onc.2008.274","volume":"27","author":"R Schickel","year":"2008","unstructured":"Schickel R, Boyerinas B, Park SM, Peter ME. Micrornas: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene. 2008;27:5959\u201374.","journal-title":"Oncogene"},{"key":"7604_CR20","first-page":"161","volume":"2","author":"AM Ardekani","year":"2010","unstructured":"Ardekani AM, Naeini MM. The role of micrornas in human diseases. Avicenna J Med Biotechnol. 2010;2:161\u201379.","journal-title":"Avicenna J Med Biotechnol"},{"key":"7604_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40035-016-0063-3","volume":"5","author":"L Chen","year":"2016","unstructured":"Chen L, Mo M, Li G, Cen L, Wei L, Xiao Y, et al. The biomarkers of immune dysregulation and inflammation response in Parkinson disease. Transl Neurodegener. 2016;5:16.","journal-title":"Transl Neurodegener"},{"key":"7604_CR22","doi-asserted-by":"publisher","first-page":"748026","DOI":"10.3389\/fnmol.2021.748026","volume":"14","author":"T Omura","year":"2021","unstructured":"Omura T, Nomura L, Watanabe R, Nishiguchi H, Yamamoto K, Imai S, et al. Microrna-101 regulates 6-hydroxydopamine-induced cell death by targeting suppressor\/enhancer Lin-12-Like in SH-SY5Y cells. Front Mol Neurosci. 2021;14:748026.","journal-title":"Front Mol Neurosci"},{"key":"7604_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/239854","volume":"2013","author":"T Omura","year":"2013","unstructured":"Omura T, Kaneko M, Okuma Y, Matsubara K, Nomura Y. Endoplasmic reticulum stress and Parkinson\u2019s disease: the role of HRD1 in averting apoptosis in neurodegenerative disease. Oxid Med Cell Longev. 2013;2013:239854.","journal-title":"Oxid Med Cell Longev"},{"key":"7604_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.parkreldis.2011.10.016","volume":"18","author":"MA van der Marck","year":"2012","unstructured":"van der Marck MA, Dicke HC, Uc EY, Kentin ZH, Borm GF, Bloem BR, et al. Body mass index in Parkinson\u2019s disease: a meta-analysis. Parkinsonism Relat Disord. 2012;18:263\u20137.","journal-title":"Parkinsonism Relat Disord"},{"key":"7604_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1152\/jn.00363.2023","volume":"131","author":"Y Li","year":"2024","unstructured":"Li Y, Liu Y, Du C, Wang J. Body mass index in patients with parkinson\u2019s disease: a systematic review. J Neurophysiol. 2024;131:311\u201320.","journal-title":"J Neurophysiol"},{"key":"7604_CR26","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2877728","volume":"2022","author":"X Yin","year":"2022","unstructured":"Yin X, Wang M, Wang W, Chen T, Song G, Niu Y, et al. Identification of potential miRNA-mRNA regulatory network contributing to Parkinson\u2019s disease. Parkinsons Dis. 2022;2022:2877728.","journal-title":"Parkinsons Dis"},{"key":"7604_CR27","doi-asserted-by":"publisher","first-page":"218","DOI":"10.3389\/fnins.2019.00218","volume":"13","author":"Z Yang","year":"2019","unstructured":"Yang Z, Li T, Cui Y, Li S, Cheng C, Shen B, et al. Elevated plasma microRNA-105-5p level in patients with idiopathic parkinson\u2019s disease: a potential disease biomarker. Front Neurosci. 2019;13:218.","journal-title":"Front Neurosci"},{"key":"7604_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JPD-012144","volume":"2","author":"SK Khoo","year":"2012","unstructured":"Khoo SK, Petillo D, Kang UJ, Resau JH, Berryhill B, Linder J, et al. Plasma-based circulating microRNA biomarkers for Parkinson\u2019s disease. J Parkinsons Dis. 2012;2:321\u201331.","journal-title":"J Parkinsons Dis"},{"key":"7604_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/cells10010113","volume":"10","author":"D Siedlecki-Wullich","year":"2021","unstructured":"Siedlecki-Wullich D, Mi\u00f1ano-Molina AJ, Rodr\u00edguez-\u00c1lvarez J. MicroRNAs as early biomarkers of alzheimer\u2019s disease: a synaptic perspective. Cells. 2021;10:113.","journal-title":"Cells"},{"key":"7604_CR30","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41419-022-05153-5","volume":"13","author":"A Ajoolabady","year":"2022","unstructured":"Ajoolabady A, Lindholm D, Ren J, Pratico D. ER stress and UPR in alzheimer\u2019s disease: mechanisms, pathogenesis, treatments. Cell Death Dis. 2022;13:706.","journal-title":"Cell Death Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07604-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-025-07604-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-025-07604-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:35:07Z","timestamp":1768386907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-025-07604-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7604"],"URL":"https:\/\/doi.org\/10.1186\/s13104-025-07604-6","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human plasma samples were purchased from KAC Co., Ltd., which obtained them from ProteoGenex Inc. (Culver City, USA). We confirmed that ProteoGenex obtained informed consent from all donors, including healthy donors and patients with PD, at the time of sample collection. In addition, the Ethical Committee of Kobe University Hospital determined that an ethical review was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}